NCT02589847: A trial that was reported late by Rebiotix Inc.
This trial has reported, although it was 668 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02589847 |
|---|---|
| Title | An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Oct. 31, 2015 |
| Completion date | June 30, 2017 |
| Required reporting date | June 30, 2018, midnight |
| Actual reporting date | April 28, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 668 |